Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Company Growth (employees)
Type
Public
HQ
Princeton, US
Founded
2002
Size (employees)
108 (est)+20%
Advaxis was founded in 2002 and is headquartered in Princeton, US

Key People/Management at Advaxis

Anthony Lombardo

Anthony Lombardo

Interim CEO
Thomas J. McKearn

Thomas J. McKearn

Director
Roni A. Appel

Roni A. Appel

Director
Richard Berman

Richard Berman

Director
Robert G. Petit

Robert G. Petit

Executive Vice President and Chief Scientific Officer

Advaxis Office Locations

Advaxis has an office in Princeton
Princeton, US (HQ)
305 College Rd E
Show all (1)

Advaxis Financials and Metrics

Advaxis Financials

Advaxis's revenue was reported to be $12 m in FY, 2017
USD

Revenue (FY, 2017)

12 m

Net income (FY, 2017)

(93.4 m)

EBIT (FY, 2017)

(98.5 m)

Market capitalization (23-Feb-2018)

76.4 m

Cash (31-Oct-2017)

23.9 m
Advaxis's current market capitalization is $76.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.9 m1 m4 m12 m

Revenue growth, %

(46%)

R&D expense

48.8 m71.9 m

General and administrative expense

31.7 m38.7 m
USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

250 k3.8 m3.4 m3.1 m

R&D expense

1.6 m7.3 m13.1 m8.8 m10.1 m13.6 m16.3 m17.8 m

General and administrative expense

4.4 m6.3 m7.1 m6.8 m6.4 m7.3 m7.8 m18.1 m

Operating expense total

6 m13.6 m20.2 m15.6 m16.6 m21 m24.1 m35.9 m
USDFY, 2013FY, 2014FY, 2016FY, 2017

Cash

20.6 m17.6 m112.8 m23.9 m

Accounts Receivable

80.1 k

Current Assets

20.8 m20.5 m159.9 m81.2 m

PP&E

7.1 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015

Cash

16 m27.6 m22.1 m30.6 m45.9 m

Current Assets

16.2 m28 m23.3 m31.5 m48.6 m

Total Assets

18.9 m30.9 m26.1 m34.5 m51.7 m

Accounts Payable

2.3 m1.6 m1.7 m1.5 m3 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    (20 m)(16.5 m)(73.6 m)(93.4 m)

    Depreciation and Amortization

    19.3 k27.6 k283.5 k790.6 k

    Accounts Receivable

    65.2 k

    Accounts Payable

    (1.9 m)8.4 m1.2 m
    USDQ1, 2014Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (5.2 m)(13.6 m)(19.8 m)(15.5 m)(16.5 m)(17.1 m)(20.5 m)

    Depreciation and Amortization

    6.9 k

    Accounts Receivable

    152.3 k164.6 k140.2 k181 k192.3 k226.8 k

    Accounts Payable

    2.2 m843.5 k5.6 m2.6 m3.5 m9.7 m3 m
      USDY, 2017

      Revenue/Employee

      125.3 k

      Financial Leverage

      1.7 x
      Show all financial metrics

      Advaxis Market Value History

      Advaxis's Web-traffic and Trends

      Advaxis Online and Social Media Presence

      Advaxis Company Life and Culture

      You may also be interested in